Start complement inhibition (eculizumab/ravulizumab)

•Patient receives antimeningococal vaccination
•Starts ravulizumab according to spc on ciprofloxacin prophylaxis
•Complement testing: low C3,C4 and increased soluble C5b-9
•Genetic testing: no known complement-related variant
•Patient responds to ravulizumab with normalization of laboratory values and no TMA-related event
Would you stop complement inhibitor after 6 months?

  • All answers
  • Yes, because the patient and caregiver consent, the patient has no known variant and complete clinical response
  • Thrombotic microangiopathy (TMA)
  • No, although the patient and caregiver consent, the patient has no known mutation and complete clinical response

Map: TMA (792)
Node: 16363
Score:

reset

OpenLabyrinth
OpenLabyrinth is an open source educational pathway system

Review your pathway

  • Start complement inhibition (eculizumab/ravulizumab)

Reminder

FINISH

Time is up